Development and validation of a novel mRNA signature for predicting early relapse in non-small cell lung cancer
ConclusionsWe successfully established a reliable signature for predicting early relapse in stage I –III non-small cell lung cancer.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer | Training | Universities & Medical Training